148 related articles for article (PubMed ID: 12866577)
61. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases.
Gancberg D; Lespagnard L; Rouas G; Paesmans M; Piccart M; Di Leo A; Nogaret JM; Hertens D; Verhest A; Larsimont D
Am J Clin Pathol; 2000 May; 113(5):675-82. PubMed ID: 10800400
[TBL] [Abstract][Full Text] [Related]
62. ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization.
Young SR; Liu WH; Brock JA; Smith ST
Genes Chromosomes Cancer; 1996 Jun; 16(2):130-7. PubMed ID: 8818660
[TBL] [Abstract][Full Text] [Related]
63. Expression of HER-2/neu oncogene in normal, hyperplastic, and malignant endometrium.
Rasty G; Murray R; Lu L; Kubilis P; Benrubi G; Masood S
Ann Clin Lab Sci; 1998; 28(3):138-43. PubMed ID: 9646853
[TBL] [Abstract][Full Text] [Related]
64. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
[TBL] [Abstract][Full Text] [Related]
65. Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus.
Jiko K; Sasano H; Ito K; Ozawa N; Sato S; Yajima A
Anticancer Res; 1993; 13(2):305-10. PubMed ID: 8517643
[TBL] [Abstract][Full Text] [Related]
66. HER2 expression in breast cancer with nonamplified HER2 and gains of chromosome 17 centromere.
Panvichian R; Tantiwetrueangdet A; Wongwaisayawan S; Nampoon A; Lertsithichai P; Leelaudomlipi S
Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):367-74. PubMed ID: 22417858
[TBL] [Abstract][Full Text] [Related]
67. [Amplification and expression of c-erbB2 oncogene in normal, hyperplastic, and malignant endometria].
Lu Y; Czerwenka K; Heuss F
Zhonghua Fu Chan Ke Za Zhi; 1996 Nov; 31(11):656-9. PubMed ID: 9387524
[TBL] [Abstract][Full Text] [Related]
68. Heterogeneity of erbB-2 gene amplification in bladder cancer.
Sauter G; Moch H; Moore D; Carroll P; Kerschmann R; Chew K; Mihatsch MJ; Gudat F; Waldman F
Cancer Res; 1993 May; 53(10 Suppl):2199-203. PubMed ID: 8097962
[TBL] [Abstract][Full Text] [Related]
69. HER-2/neu in breast cancer: a comparative study between histology, immunohistochemistry, and molecular technique (FISH).
Rossi E; Ubiali A; Cadei M; Balzarini P; Valagussa E; Lucini L; Alpi F; Galletti A; Fontana L; Tedoldi C; Grigolato P
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):127-31. PubMed ID: 16785778
[TBL] [Abstract][Full Text] [Related]
70. Amplification of Mycn, Ddx1, Rrm2, and Odc1 in rat uterine endometrial carcinomas.
Karlsson A ; Helou K; Walentinsson A; Hedrich HJ; Szpirer C; Levan G
Genes Chromosomes Cancer; 2001 Aug; 31(4):345-56. PubMed ID: 11433525
[TBL] [Abstract][Full Text] [Related]
71. c-erbB2 oncoprotein expression, gene amplification, and chromosome 17 aneusomy in apocrine adenosis of the breast.
Selim AG; El-Ayat G; Wells CA
J Pathol; 2000 Jun; 191(2):138-42. PubMed ID: 10861572
[TBL] [Abstract][Full Text] [Related]
72. [Significance of her2 oncogene expression in primary nasopharyngeal carcinoma].
Yan J; Fang Y; Jiao Y
Zhonghua Yi Xue Za Zhi; 2001 Aug; 81(15):904-6. PubMed ID: 11702662
[TBL] [Abstract][Full Text] [Related]
73. Independent amplification of two gene clusters on chromosome 4 in rat endometrial cancer: identification and molecular characterization.
Walentinsson A; Helou K; Wallenius V; Hedrich HJ; Szpirer C; Levan G
Cancer Res; 2001 Nov; 61(22):8263-73. PubMed ID: 11719459
[TBL] [Abstract][Full Text] [Related]
74. [Evaluation of her-2/neu amplification/overexpression in OSCC with fluorescence in situ hybridization (FISH) and immunohistochemistry].
Scheer M; Prange W; Petmecky K; Schirmacher P; Zöller JE; Kübler AC
Mund Kiefer Gesichtschir; 2003 May; 7(3):138-45. PubMed ID: 12764679
[TBL] [Abstract][Full Text] [Related]
75. Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus.
Troxell ML; Bangs CD; Lawce HJ; Galperin IB; Baiyee D; West RB; Olson SB; Cherry AM
Am J Clin Pathol; 2006 Nov; 126(5):709-16. PubMed ID: 17050068
[TBL] [Abstract][Full Text] [Related]
76. Efficacy of primed in situ labelling in determination of HER-2 gene amplification and CEN-17 status in breast cancer tissue.
Salimi M; Mozdarani H; Majidzadeh-A K
Asian Pac J Cancer Prev; 2012; 13(1):329-37. PubMed ID: 22502695
[TBL] [Abstract][Full Text] [Related]
77. Assessment of HER-2/neu, с-MYC and CCNE1 gene copy number variations and protein expression in endometrial carcinomas.
Buchynska LG; Brieieva OV; Iurchenko NP
Exp Oncol; 2019 Jun; 41(2):138-143. PubMed ID: 31262163
[TBL] [Abstract][Full Text] [Related]
78. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Grushko TA; Filiaci VL; Mundt AJ; Ridderstråle K; Olopade OI; Fleming GF;
Gynecol Oncol; 2008 Jan; 108(1):3-9. PubMed ID: 17945336
[TBL] [Abstract][Full Text] [Related]
79. HER-2/neu oncogene amplification in cervical cancer studied by fluorescent in situ hybridization.
Mark HF; Feldman D; Das S; Sun CL; Samy M; Lathrop J
Genet Test; 1999; 3(2):237-42. PubMed ID: 10464675
[TBL] [Abstract][Full Text] [Related]
80. Epidermal growth factor receptor overexpression/amplification in adenocarcinomas arising in the gastrointestinal tract.
Rossi E; Villanacci V; Danesino C; Donato F; Nascimbeni R; Bassotti G
Rev Esp Enferm Dig; 2011 Dec; 103(12):632-9. PubMed ID: 22217347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
